Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC SODIUM versus TAB PROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC SODIUM versus TAB PROFEN.
DICLOFENAC SODIUM vs TAB-PROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis via inhibition of cyclooxygenase, leading to anti-inflammatory, analgesic, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor; reduces prostaglandin synthesis.
Oral: 50 mg two to three times daily; maximum 150 mg/day. Topical: 1% gel applied four times daily. Rectal: 100 mg suppository once daily.
400-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.3–3.1 h). Short half-life requires frequent dosing; no accumulation with normal dosing intervals.
The terminal elimination half-life is 2-4 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Approximately 65% renal as glucuronide conjugates and inactive metabolites, ~20% biliary/fecal. Less than 1% unchanged in urine.
Renal excretion of unchanged drug accounts for approximately 70-90% of the administered dose, with the remainder eliminated as glucuronide conjugates in urine. Biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
NSAID
NSAID